Cargando…
Radiographic progression in clinical trials in rheumatoid arthritis: a systemic literature review of trials performed by industry
OBJECTIVES: To summarise radiographic data in randomised controlled trials (RCTs) as part of the radiographic inhibition claim of disease-modifying antirheumatic drugs (DMARDs) approved for patients with rheumatoid arthritis (RA). METHODS: A systemic literature review was performed using the Medline...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425197/ https://www.ncbi.nlm.nih.gov/pubmed/32669455 http://dx.doi.org/10.1136/rmdopen-2020-001277 |
_version_ | 1783570451930284032 |
---|---|
author | Park, Yune-Jung Gherghe, Ana Maria van der Heijde, Desirée |
author_facet | Park, Yune-Jung Gherghe, Ana Maria van der Heijde, Desirée |
author_sort | Park, Yune-Jung |
collection | PubMed |
description | OBJECTIVES: To summarise radiographic data in randomised controlled trials (RCTs) as part of the radiographic inhibition claim of disease-modifying antirheumatic drugs (DMARDs) approved for patients with rheumatoid arthritis (RA). METHODS: A systemic literature review was performed using the Medline database from 1994 to February 2020. The results were grouped based on the scoring methods (Sharp, Genant modification, van der Heijde modification) and RA patient populations. RESULTS: One hundred sixty-eight publications were selected. After detailed assessment, 52 RCTs (7 methotrexate (MTX)-naive, 23 MTX inadequate response (IR), 9 DMARDs IR and 3 tumour necrosis factor-alpha inhibitors (TNFi) IR studies) were finally included. Information on patient population, scoring method used, reader reliability, statistical analyses and detailed radiographic data on baseline and change scores over multiple follow-up periods are presented. CONCLUSION: The data gathered in this review serve as a repository for the design of future trials with radiographic damage as an outcome. |
format | Online Article Text |
id | pubmed-7425197 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-74251972020-08-24 Radiographic progression in clinical trials in rheumatoid arthritis: a systemic literature review of trials performed by industry Park, Yune-Jung Gherghe, Ana Maria van der Heijde, Desirée RMD Open Rheumatoid Arthritis OBJECTIVES: To summarise radiographic data in randomised controlled trials (RCTs) as part of the radiographic inhibition claim of disease-modifying antirheumatic drugs (DMARDs) approved for patients with rheumatoid arthritis (RA). METHODS: A systemic literature review was performed using the Medline database from 1994 to February 2020. The results were grouped based on the scoring methods (Sharp, Genant modification, van der Heijde modification) and RA patient populations. RESULTS: One hundred sixty-eight publications were selected. After detailed assessment, 52 RCTs (7 methotrexate (MTX)-naive, 23 MTX inadequate response (IR), 9 DMARDs IR and 3 tumour necrosis factor-alpha inhibitors (TNFi) IR studies) were finally included. Information on patient population, scoring method used, reader reliability, statistical analyses and detailed radiographic data on baseline and change scores over multiple follow-up periods are presented. CONCLUSION: The data gathered in this review serve as a repository for the design of future trials with radiographic damage as an outcome. BMJ Publishing Group 2020-07-14 /pmc/articles/PMC7425197/ /pubmed/32669455 http://dx.doi.org/10.1136/rmdopen-2020-001277 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Rheumatoid Arthritis Park, Yune-Jung Gherghe, Ana Maria van der Heijde, Desirée Radiographic progression in clinical trials in rheumatoid arthritis: a systemic literature review of trials performed by industry |
title | Radiographic progression in clinical trials in rheumatoid arthritis: a systemic literature review of trials performed by industry |
title_full | Radiographic progression in clinical trials in rheumatoid arthritis: a systemic literature review of trials performed by industry |
title_fullStr | Radiographic progression in clinical trials in rheumatoid arthritis: a systemic literature review of trials performed by industry |
title_full_unstemmed | Radiographic progression in clinical trials in rheumatoid arthritis: a systemic literature review of trials performed by industry |
title_short | Radiographic progression in clinical trials in rheumatoid arthritis: a systemic literature review of trials performed by industry |
title_sort | radiographic progression in clinical trials in rheumatoid arthritis: a systemic literature review of trials performed by industry |
topic | Rheumatoid Arthritis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425197/ https://www.ncbi.nlm.nih.gov/pubmed/32669455 http://dx.doi.org/10.1136/rmdopen-2020-001277 |
work_keys_str_mv | AT parkyunejung radiographicprogressioninclinicaltrialsinrheumatoidarthritisasystemicliteraturereviewoftrialsperformedbyindustry AT ghergheanamaria radiographicprogressioninclinicaltrialsinrheumatoidarthritisasystemicliteraturereviewoftrialsperformedbyindustry AT vanderheijdedesiree radiographicprogressioninclinicaltrialsinrheumatoidarthritisasystemicliteraturereviewoftrialsperformedbyindustry |